ClinicalTrials.gg
RecruitingNCT06525571Updated Nov 3, 2026

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

A Phase 3 interventional study of Cysview and Karl Storz D-Light C Photodynamic Diagnostic (PDD) system in Bladder Cancer, sponsored by Johns Hopkins University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Johns Hopkins University · Phase 3, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing hexaminolevulinate hydrochloride in Urinary Bladder Neoplasms — 1 open to participants now, 1 under way, 1 of them phase 3. hexaminolevulinate hydrochloride · Urinary Bladder Neoplasms.

Started
2024
the only one that year
Phase 3
7 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Johns Hopkins University

Among the 10 studies testing hexaminolevulinate hydrochloride in Urinary Bladder Neoplasms, this one is the only one that started in 2024, is one of 7 in phase 3, and was the 10th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

1 of the 10 studies testing hexaminolevulinate hydrochloride in Urinary Bladder Neoplasms is open now, in 1 country.

By country, each count listing its studies:

About hexaminolevulinate hydrochloride

hexaminolevulinate hydrochloride: first FDA approval 2010 (CYSVIEW KIT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing hexaminolevulinate hydrochloride in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.

Read the detailed description

Objectives are as follows:

Primary i) Comparison of the reduction in MRD burden score between pre-resection and post-resection urine samples across BLC and WLC resection arms of the study, and among patients with a high-grade tumor at time of resection ii) Comparison of the reduction in MRD burden score between pre-resection and post-resection urine samples across BLC and WLC resection arms of the study, and among all evaluable study participants.

Secondary i) Among all evaluable study participants: Recurrence-free survival (RFS) at 12 and 24 months using post-TURBT and three month surveillance urine sample time points in BLC and WLC arm.

ii) Among patients undergoing intravesical induction: Recurrence-free survival (RFS) at 12 and 24 months using post-TURBT and three month surveillance urine sample time points in BLC and WLC arm.

03

Conditions studied

  • Bladder Cancer

Keywords

  • Blue light cystoscopy
  • Cysview
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing TURBT for radiographic or cystoscopic positive tumor
  • 18+ years old
  • Upper tract evaluated using standard of care throughout duration of the study
  • Induction intravesical therapy initiated within four weeks of TURBT

Exclusion criteria

Exclusion Criteria:

  • Variant histology consisting of less than 50% urothelial carcinoma
  • History, or current diagnosis, of upper tract tumor or muscle-invasive bladder cancer
  • Prior history of pelvic radiation
  • Active urinary tract infection (UTI)
  • Patients who are noncompliant with the study protocol
05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Blue light Cystoscopy

    Patients with bladder tumors will undergo BLC TURBT

    Drug: Cysview · Device: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system

  • Active comparator
    White light Cystoscopy

    Patients with bladder tumors will undergo WLC TURBT

    Device: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system

Interventions

  • DrugHexaminolevulinate hydrochlorideStudies of Hexaminolevulinate hydrochlorideHexaminolevulinate hydrochloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.

    Also known as: Hexyl aminolevulinate (HAL)

  • DeviceKarl Storz D-Light C Photodynamic Diagnostic (PDD) system

    Cystoscopy procedure

    Also known as: Cystoscopy equipment to detect Cysview uptake in the bladder tumors

06

What researchers measure

Primary outcomes

  1. Residual disease burden

    The residual tumor burden will be assessed by the standard of care testing, such as cystoscopy and cytology at 3 month intervals.

    Time frame: Up to 24 months

  2. Minimal residual disease burden

    Minimal residual disease (MRD) in urine will be measured utilizing the Convergent's UroAmp test at 3 month intervals.

    Time frame: Up to 24 months

Secondary outcomes

  1. Recurrence-free survival

    Recurrence-free survival rate will measured from the date of randomization to the first recurrence or to death from any cause.

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

Of 73 phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 85. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 29, 2024
StartActual
Dec 20, 2024
Primary completionEst.
Jan 4, 2027
CompletionEst.
Jan 4, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06525571
Collaborators
Photocure ASA
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Dec 20, 2024
Primary completion
Jan 4, 2027 (estimated)
Completion
Jan 4, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Domani Rodriguez
Contact
drodri59@jh.edu
2026605561
Armine Smith, MD
Contact
asmit165@jhmi.edu
2026605561
Armine Smith, MD
principal investigator · Sibley Memorial Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hexaminolevulinate hydrochloride

Start the discussion